相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Enhanced interleukin-2 diphtheria toxin conjugate-induced growth suppression in retinoic acid-treated hypoxic hepatocellular carcinoma cells
Bo Hyun Kim et al.
CANCER LETTERS (2009)
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines
Jens Ruter et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
De novo maintenance therapy with denileukin diftitox (Ontak®) in a patient with peripheral T-cell lymphoma is associated with prolonged remission
Bryan Y. Wong et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Transient T cell depletion causes regression of melanoma metastases
Mary Ann Rasku et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Cutaneous γ/δ T-cell lymphoma treated with radiation and denileukin diftitox
Kelley Vidulich et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
Nam H. Dang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Depletion of CD4+CD25+ human regulatory T cells in vivo:: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro
Karsten Mahnke et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
Nam H. Dang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia
AE Frankel et al.
CANCER (2006)
Lymphorna incidence patterns by WHO subtype in the United States, 1992-2001
LM Morton et al.
BLOOD (2006)
Regulatory T cells in ovarian cancer: Biology and therapeutic potential
B Barnett et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2005)
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
P Attia et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease
PJ Shaughnessy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Denileukin diftitox: a concise clinical review
JW Eklund et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2005)
Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma
NH Dang et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated adult T-cell leukemia/lymphoma
G DiVenuti et al.
CLINICAL LYMPHOMA (2003)
DAB389IL2 (ONTAK®) fusion protein therapy of chronic lymphocytic leukaemia
AE Frankel et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2003)
A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB389 IL-2) in patients with severe psoriasis
A Martin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2001)
分享论文
